Hidradenitis Suppurativa (HS): Opportunity Analysis and Forecast to 2034

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the HS market through 2034.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition with multifactorial etiology. Although its pathogenesis is not fully known, current evidence implicates genetic susceptibility, hormonal influences, environmental and lifestyle factors, microbial involvement, and immune dysregulation as central to disease initiation and propagation. These elements interact within a vulnerable follicular environment, culminating in the characteristic clinical features of HS.

The HS market across the 7MM was valued at $1.84 billion in 2024. Over the 10-year forecast period, the market is projected to grow at a CAGR of 15.6%, reaching $7.80 billion by 2034. The major driver for this growth will be the launch of several pipeline agents including the introduction of new biologics and small molecules, including MoonLake Therapeutics' sonelokimab and Incyte's povorcitnib.

Key Highlights

• Report deliverables include a Pdf report and Excel-based forecast model
• Forecasts includes the 7MM
• Forecasts covers from 2024-2034

Scope

• Overview of HS, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized HS treatment market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the HS therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for HS treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
• Analysis of the current and future market competition in the global HS therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM HS therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM HS therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.